NorthStar Starts Construction of Moly-99 Facility

NorthStar Medical Radioisotopes broke ground yesterday on its new 50,000 square foot facility in Beloit, Wis. that will host its headquarters and activities related to the production of molybdenum-99 (Moly-99). NorthStar is one of several companies looking to take advantage of the up-coming Moly-99 shortage in 2016, and the company is currently seeking Food and Drug Administration approval for its production process. According to the company, the facility, expected to be completed by the end of 2014, will provide ancillary processes, packaging, and products, including final assembly and testing of the proprietary RadioGenix intelligent isotope separation system. “Today’s groundbreaking is an exciting milestone for NorthStar Medical Radioisotopes and an important step toward achieving the goal of establishing a reliable and commercially viable domestic source of Mo-99,” NorthStar President and CEO George Messina said in a statement.